Experimental respiratory infections were established in mice by intranasal inoculation of Streptococcus pneumoniae. Inoculation of 107 CFU of either S. pneumoniae 1629 or S. pneumoniae 7 produced a fatal pneumonia in nontreated mice 2 to 3 days after infection. Oral therapy was commenced 1 h after infection and was continued three times a day for 2 days. The doses used in mice produced peak concentrations in serum and lung tissue similar to those measured in humans. Ciprofloxacin failed to eliminate either strain of pneumococcus from mouse lungs at any of the doses tested (40, 80, or 160 mg/kg of body weight) by the end of therapy (33 h). Mice that received ciprofloxacin at 160 mg/kg were clear of S. pneumoniae 7 5 days later, whereas persistence and regrowth of S. pneumoniae 1629 resulted in the death of 20% of animals treated with ciprofloxacin. Therapy with cefaclor (20 mg/kg) produced an effect similar to that of ciprofloxacin. In contrast, amoxicillin (10 and 20 mg/kg) and amoxicillin-clavulanic acid (10/5 and 20/10 mg/kg) were significantly (P < 0.05) more effective in eliminating both strains of S. pneumoniae from the lungs by the end of therapy and, by 168 h, had prevented mortality in 80 to 100% of treated animals. The efficacy of ciprofloxacin against these experimental pneumococcal respiratory infections was poor, despite good penetration into lung tissue, and is a reflection of the low in vitro activity of the quinolone against S. pneumoniae, one of the most common pathogens in community-acquired pneumonia.
Pneumonia has been reported to be one of the most serious infectious diseases in both industrialized and underdeveloped countries (2) and is a major cause of morbidity and mortality. Approximately 7% of patients with community-acquired pneumonia require hospitalization, and there is a 5 to 10% mortality rate in such patients. Streptococcus pneumoniae remains a highly prevalent pathogen in adult patients (10, 18) , and recovery of this organism in 9 to 42% of patients with community-acquired pneumonia has been recorded over the past decade (2) . Other organisms implicated in lower respiratory infections include Haemophilus influenzae and Branhamella catarrhalis, while Staphylococcus aureus, Legionella pneumophila, influenza A virus, and Mycoplasma pneumoniae are less common causes of community-acquired pneumonia or cause atypical pneumonias (8) .
Ampicillin and amoxicillin are the most frequently prescribed agents for the oral treatment of lower respiratory tract infections (28) and are generally highly effective against S. pneumoniae and non-p-lactamase-producing H. influenzae. Both agents are, however, less satisfactory for infections in which ,-lactamase-producing organisms such as H. influenzae, B. catarrhalis, or gram-negative bacilli may be present. In such cases, the combination of amoxicillin and the ,-lactamase inhibitor clavulanic acid has been reported to be highly efficacious (3) .
In recent years there has been great interest in the role of the 4-fluoroquinolones in the treatment of lower respiratory tract infections. Potential advantages of this class of agents include good absorption following oral administration, good penetration into tissues, and a broad spectrum of antimicrobial activity. In the treatment of respiratory infections, * Corresponding author. ciprofloxacin, the quinolone carboxylic acid derivative, has been reported to be as effective as ampicillin (27) and amoxicillin-clavulanic acid (15) and superior to the oral cephalosporin cefaclor (13) . However, because ciprofloxacin shows poor in vitro activity against S. pneumoniae, caution has been advised in the empiric use of the quinolone for the treatment of lower respiratory infections (17, 26) . While the failure of ciprofloxacin therapy because of the presence of S. pneumoniae in bronchopulmonary infections has been seen (6, 25) , other reports suggest that the reduced susceptibility of pneumococci does not interfere with the efficacy of the drug (4, 7, 20) . Indeed, ciprofloxacin penetrates the bronchial mucosa efficiently and has been reported to reach concentrations in the tissue in excess of that required to inhibit 90% of S. pneumoniae (11, 14) , and therefore, it might be considered to be effective in vivo.
Although the efficacy of ciprofloxacin has been demonstrated in a number of experimental models of pneumonia by using H. influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa (12, 21, 22) , no data have been published on the efficacy of this quinolone against an experimental S. pneumoniae pneumonia, and the requirement for further investigations has been suggested (5, 14) .
In the studies reported here, the efficacies of ciprofloxacin, amoxicillin, amoxicillin-clavulanic acid, and cefaclor were assessed by using a model of acute S. pneumoniae pneumonia in mice.
Hewitt broth (Oxoid) and frozen in 1-ml aliquots at -70°C. For each experiment, 200-pd volumes of a thawed suspension were used to seed 5-ml volumes of fresh Todd-Hewitt broth, which were incubated overnight at 37°C to yield approximately 108 CFU/ml. The MICs of the agents used in the therapy studies were determined according to the recommendations of the National Committee for Clinical Laboratory Standards (16 Assessment of therapy. The numbers of mice that survived were recorded for 7 days. One hour after infection, control mice (n = 5) were killed to determine the numbers of the infecting organism present in the lung tissue at the initiation of therapy. Thereafter, groups of five mice per treatment were sampled at 33 h (2 h after the final dose) and 168 h after infection. The lungs were removed aseptically and washed in phosphate-buffered saline to remove contaminating blood. The lungs were then homogenized in glass tissue grinders containing 1 ml of Todd-Hewitt broth. Homogenates were serially diluted in Todd-Hewitt broth, and 20-pd volumes were plated in triplicate onto 5% blood agar supplemented with 0.5% (vol/vol) ,-lactamase (penase; Difco) and incubated at 37°C for 24 h to determine the number of viable S. pneumoniae present. Confirmation of the recovery of S. pneumoniae from the lung tissue was made by Gram stain and determination of optochin susceptibility (5-,ug disk; Mast Laboratories, Liverpool, England). Animals that became moribund prior to the designated sampling times were humanely killed and the lungs were sampled. On occasions when an animal died before a sample could be obtained, mean bacterial counts (7.69 or 8.34 log1o CFU) from moribund mice were substituted.
Distribution. In separate studies, concentrations of the agents were measured in serum and lung tissue of infected mice dosed 1 h after inoculation with S. pneumoniae 1629. Infected animals received a single oral dose of amoxicillinclavulanic acid (20/10 mg/kg), cefaclor (20 mg/kg), or ciprofloxacin (40, 80, or 160 mg/kg). At intervals after dosing, groups of five animals per treatment were humanely killed, and blood was obtained from the axillary vein and centrifuged at 15,000 x g for 2 min to obtain a serum fraction. The lungs were removed and rendered free of surface blood by blotting before being homogenized in glass tissue grinders containing 1 (Fig. 2) 2) and remained clear of the infecting organism. The mean numbers of S. pneumoniae 1629 recovered from these groups were significantly lower (P < 0.05) than those obtained from cefaclor-treated animals or those mice that received 40 or 80 mg of ciprofloxacin per kg (Fig. lb) .
Similarly, treatment with amoxicillin-clavulanic acid, 10/5 and 20/10 mg/kg, produced a significantly greater (P < 0.05) reduction in the lung pneumococcal count by 33 h (Fig. la) than did therapy with either ciprofloxacin or cefaclor. As with the groups treated with amoxicillin alone, the majority of animals that received amoxicillin-clavulanic acid had no detectable S. pneumoniae 1629 present in the lung tissue when sampled at the end of the study (Fig. lb) .
Susceptibility testing of the S. pneumoniae 1629 isolates recovered from the lungs during this study failed to show any alteration in susceptibility to any of the agents.
(ii) Study 2: S. pneumoniae 7. Counts of S. and 168 h postinfection are shown in Fig. 3a and b, respectively. Survival-versus-time curves are shown in Fig. 4 . The mean number of pneumococci present in the lungs of nontreated control mice at 33 h after infection was similar to that measured at 1 h, which was 7.28 ± 0.42 log1o CFU per lung.
As in mice with the S. pneumoniae 1629 infection, evidence of enlargement and consolidation of the lungs was seen at 33 h in mice infected with S. pneumoniae 7. The infection rapidly progressed to a fatal pneumonia, so that by 48 h after infection all control mice were either dead or moribund (Fig.   4) .
A clear dose response was again seen in mice treated with ciprofloxacin. Oral therapy given at 40, 80, or 160 mg/kg reduced the bacterial counts in the lungs to 4.28 ± 0.95, 3 .50 + 0.42, and 2.00 ± 1.22 loglo CFU per lung, respectively, by 33 h (Fig. 3a) . By 168 h, 60% of animals that had received 40 mg of ciprofloxacin per kg had died or were moribund (Fig.  4) , although the remaining animals were clear of the infecting organism. In the groups dosed with either 80 or 160 mg of ciprofloxacin per kg, 80 to 100% of the mice that survived to 168 h yielded no pneumococci (Fig. 3b) .
Treatment with cefaclor at 20 mg/kg reduced the S. pneumoniae 7 count to 3.26 + 2.01 log10 CFU per lung by 33 h after infection (Fig. 3a) , and pneumococci could not be detected in the lungs of cefaclor-treated animals at the end of the study (Fig. 3b) .
Therapy with amoxicillin (10 or 20 mg/kg) alone or in combination with clavulanic acid (5 or 10 mg/kg) reduced the numbers of S. pneumoniae 7 to below the limit of detection (<33 CFU per lung) in all treatment groups by 33 h (Fig. 3a) . As with therapy against S. pneumoniae 1629, the reduction in the S. pneumoniae 7 lung count was significantly greater (P < 0.05) than that achieved with the other antibiotics tested. All treated mice were alive at 168 h postinfection (Fig. 4) . Of the animals that received amoxicillin (10 mg/kg) alone or in combination with clavulanic acid (5 mg/kg), 80% were clear of the infecting organism; the one remaining animal in each of these groups yielded counts of 3.30 and 4.36 log1o CFU per lung, respectively (Fig. 3b) . S. pneumoniae 7 could not be isolated from the lungs of mice treated with amoxicillin (20 mg/kg) or amoxicillin-clavulanic acid (20/10 mg/kg) when samples were obtained at 168 h.
In subsequent in vitro testing, the isolates of S. pneumoniae 7 recovered from the lungs of mice sampled in this study showed no alteration in susceptibility to the agents used.
DISCUSSION
The experimental model used here produced an acute pneumonia in mice and represents a strict test for any antibiotic because of the rapid onset of a fatal infection. Both strains of S. pneumoniae used were highly virulent in mice, although persistence and subsequent regrowth of the mucoid S. pneumoniae 1629 strain after cessation of therapy was more evident than was the case with S. pneumoniae 7. The doses of the antibiotics administered to mice in the therapy studies produced peak concentrations in serum and lung tissue of the same order as those achieved in humans, except for the highest dose of ciprofloxacin, which was clearly in excess. Penetration of the agents into mouse lung tissue was also of the same order as that quoted for humans (11, 23) .
These studies demonstrated that, although it reduced the pneumococcal count, therapy with ciprofloxacin failed to eliminate these strains of S. pneumoniae, even when high doses of the agent were used and good penetration into the lung tissue was achieved. Eventual removal of S. pneumoniae 7 occurred after cessation of treatment with the higher doses of ciprofloxacin, but failure to eradicate S. pneumoniae 1629 during therapy led to regrowth of the organism and death of animals when treatment ended. The emergence of resistant S. pneumoniae strains in cases of therapy failure was not demonstrated in these studies.
The in vitro activity of cefaclor against these strains of S. pneumoniae was similar to that of ciprofloxacin, and the response of infected mice to treatment with cefaclor was similar to that achieved with the quinolone. Cefaclor was chosen as a standard agent because it is widely used for the treatment of community-acquired pneumonia. Its poor efficacy in these studies was unexpected. However, this can probably be explained by the low lung tissue concentrations attained, which barely exceeded the MICs for the strains used.
In contrast, therapy with either amoxicillin or amoxicillinclavulanic acid eliminated both strains of S. pneumoniae in the majority of treated mice by the end of the therapy period and thus prevented mortality. Although penetration of amoxicillin into lung tissue was not as efficient as that of ciprofloxacin, the concentrations achieved were in excess of the MICs for the two strains. The results of these studies concur with those of others (19) , who demonstrated the superior activity of amoxicillin vis-A-vis the variable efficacy of the quinolones in experimental models of pneumonia. Although the presence of the 13-lactamase inhibitor played no part in the efficacy of amoxicillin-clavulanic acid against the pneumococcal experimental infections reported here, studies in a rat model of pneumococcal pneumonia (24) have demonstrated the lack of efficacy of amoxicillin when P-lactamase-producing organisms were present, and the protection of amoxicillin by clavulanic acid resulted in the successful therapy of the mixed infection.
The results obtained from this experimental model of an acute S. pneumoniae respiratory infection underline the uncertainty about the effectiveness of ciprofloxacin in the treatment of respiratory infections in which S. pneumoniae may be present.
